Abstract:Multiple myeloma is a hematological malignancy characterized by the unrestricted proliferation of plasma cells that secrete monoclonal immunoglobulins in the bone marrow. Alpha-momorcharin (α-MMC) is a type I ribosome-inactivating protein extracted from the seeds of the edible plant Momordica charantia L., which has a variety of biological activities. This study aimed to investigate the inhibitory effect of α-MMC on the proliferation of multiple myeloma MM.1S cells and the molecular mechanism of MM.1S cell death induced through the activation of cell signal transduction pathways. The cell counting kit-8 (CCK-8) assay was used to determine the inhibitory effect of α-MMC on the proliferation of MM.1S cells and its toxic effect on normal human peripheral blood mononuclear cells (PBMCs). The effect of α-MMC on the MM.1S cells' morphology was observed via inverted microscope imaging. The effects of α-MMC on the MM.1S cell cycle, mitochondrial membrane potential (MMP), and apoptosis were explored using propidium iodide, JC-1, annexin V- fluorescein isothiocyanate/propidium iodide fluorescence staining, and flow cytometry (FCM) analysis. Western blot was used to detect the expressions levels of apoptosis-related proteins and MAPK-signaling-pathway-related proteins in MM.1S cells induced by α-MMC. The results of the CCK-8 showed that in the concentration range of no significant toxicity to PBMCs, α-MMC inhibited the proliferation of MM.1S cells in a time-dependent and concentration-dependent manner, and the IC50 value was 13.04 and 7.518 μg/mL for 24 and 48 h, respectively. Through inverted microscope imaging, it was observed that α-MMC induced a typical apoptotic morphology in MM.1S cells. The results of the FCM detection and analysis showed that α-MMC could arrest the MM.1S cells cycle at the G2 phase, decrease the MMP, and induce cell apoptosis. Western blot analysis found that α-MMC upregulated the expression levels of Bax, Bid, cleaved caspase-3, and cleaved PARP, and downregulated the expression levels of Mcl-1. At the same time, α-MMC decreased the expression levels of p-c-Raf, p-MEK1/2, p-ERK1/2, p-MSK1, and p-P90RSK, and increased the expression levels of p-p38, p-SPAK/JNK, p-c-Jun, and p-ATF2. The above results suggest that α-MMC can inhibit the proliferation of multiple myeloma MM.1S cells. MAPK cascade signaling is involved in the growth inhibition effect of α-MMC on MM.1S cells via cycle arrest and mitochondrial-pathway-dependent apoptosis.

Glycolysis is Suppressed by DCZ0801-induced Inactivation of the Akt/mTOR Pathway in Multiple Myeloma

Glycolysis is suppressed by DCZ0801-induced inactivation of the Akt/mTOR pathway in Multiple Myeloma.

Dcz0814 Induces Apoptosis And G0/G1 Phase Cell Cycle Arrest In Myeloma By Dual Inhibition Of Mtorc1/2

DCZ0801, a Novel Compound, Induces Cell Apoptosis and Cell Cycle Arrest Via MAPK Pathway in Multiple Myeloma.

Cmar_a_194202 4797..4808

Dual Inhibition of Mtorc1/2 by DCZ0358 Induces Cytotoxicity in Multiple Myeloma and Overcomes the Protective Effect of the Bone Marrow Microenvironment

A novel phosphoramide compound, DCZ0805, shows potent anti-myeloma activity via the NF-κB pathway

A novel alkaloid compound, DCZ0358, exerts significant antitumor activity in bortezomib-resistant multiple myeloma cells through inhibition of JAK2/STAT3 pathway

Preclinical Activity Of Dcz3301, A Novel Aryl-Guanidino Compound In The Therapy Of Multiple Myeloma

A novel silicone derivative of natural osalmid (DCZ0858) exerts anti-multiple myeloma activity by promoting cell apoptosis and inhibiting cell cycle and mTOR signaling

A Novel M Phase Blocker, DCZ3301 Enhances the Sensitivity of Bortezomib in Resistant Multiple Myeloma Through DNA Damage and Mitotic Catastrophe

The novel norcantharidin derivative DCZ5417 suppresses multiple myeloma progression by targeting the TRIP13–MAPK–YWHAE signaling pathway

A novel phosphoramide compound, DCZ0847, displays in vitro and in vivo anti-myeloma activity, alone or in combination with bortezomib

Polyphyllin I Induces Cell Cycle Arrest and Apoptosis in Human Myeloma Cells Via Modulating Β‐catenin Signaling Pathway

A novel phosphoramide compound, DCZ0847, displays <i>in vitro</i> and <i>in vivo</i> anti-myeloma activity, alone or in combination with bortezomib

A novel pterostilbene compound DCZ0825 induces macrophage M1 differentiation and Th1 polarization to exert anti-myeloma and immunomodulatory

Identification of a Novel C-Myc Inhibitor 7594-0037 by Structure-Based Virtual Screening and Investigation of Its Anti-Cancer Effect on Multiple Myeloma

Induction of cell cycle arrest and apoptosis by CPUC002 through stabilization of p53 and suppression of STAT3 signaling pathway in multiple myeloma

SR18292 Exerts Potent Antitumor Effects in Multiple Myeloma Via Inhibition of Oxidative Phosphorylation.

MAPK Cascade Signaling is Involved in Α-Mmc Induced Growth Inhibition of Multiple Myeloma MM.1S Cells Via G2 Arrest and Mitochondrial-Pathway-Dependent Apoptosis in Vitro.

A Novel Small Molecule Compound Displays Preclinical Activity Against Multiple Myeloma by Disrupting the Mtor Signaling Pathway